Why Execution Strategy Begins at the Business Decision, Not Study Startup

Full interview summary

In a recent video interview with Applied Clinical Trials, Elizabeth Walsh, PMP, ACRP-CP, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint: Aligning Strategy, Oversight, and Delivery in Clinical Development, discussed the persistent execution gaps she has observed across 25 years in clinical development—and the thinking behind her book as a structured response to them. She opened by identifying a quiet but consequential misconception embedded in how most sponsor organizations are structured: the belief that outsourcing execution transfers accountability along with the tasks. It does not. Accountability and ownership remain with the sponsor, and when that is not clearly understood and designed for, the instability that follows tends to be attributed to vendors and operational teams rather than to the conditions created much earlier.

Walsh argued that execution strategy does not begin at study startup—it begins at the business decision. The assumptions accumulated the moment a product development decision is made govern everything that follows: feasibility, vendor scoping, timelines, supply requirements. By the time those assumptions are tested at startup, they are no longer assumptions. They are embedded in contracts and commitments. The work of stress-testing them earlier is not eliminated by deferring it—it is simply pushed to where it is more expensive and harder to correct.

On capability gaps, Walsh pointed to the interpretive work of bridging scientific intent into operational reality as one of the most underappreciated skills in clinical development—one that requires judgment and pattern recognition built through experience, not administrative coordination. She also pushed back on how sponsor oversight roles are structured and staffed, noting that over-indexing on narrow therapeutic area credentials can leave consequential gaps in the implementation, integration, and leadership capabilities that actually determine execution quality.

She closed by describing what genuine inspection readiness looks like when it is built in from the outset: not a pre-inspection scramble, but a program that accumulated its evidence in real time—decisions documented as they were made, risks owned by the right functions, and a Trial Master File that tells a coherent story because the program itself was coherently run.